Long‐term mortality (time‐to‐event outcome): radiotherapy versus surgery All‐cause mortality for the duration of · patients with oesophageal cancer
It is very uncertain whether non‐surgical changes long‐term mortality (time‐to‐event outcome): radiotherapy versus… compared with surgical treatment of oesophageal cancer (primary outcomes) (very low certainty).
1 finding from 1 review
Long‐term mortality (time‐to‐event outcome): chemoradiotherapy versus surgery All‐cause mortality for the duration of · patients with oesophageal cancer
Non‐surgical showed no clear difference in long‐term mortality (time‐to‐event outcome): chemoradiotherapy… compared with surgical treatment of oesophageal cancer (primary outcomes) (low certainty).
2 findings from 1 review
All‐cause mortality ( · people with CLI who were not suitable for revascularisation and showed no improvement in response to the best standard therapy
It is very uncertain whether intramuscular injection of bone marrow mononuclear cells (BMMNC) changes all‐cause mortality ( compared with control (very low certainty).
1 finding from 1 review
Death Analysis 1.1 · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
It is very uncertain whether summary of Findings Table ‐ Antithrombin concentrates changes all‐cause mortality ‐ Intention‐to‐treat analysis compared with no antithrombin concentrates (very low certainty).
1 finding from 1 review
Long‐term mortality (binary outcome) All‐cause mortality for the duration of · patients with oesophageal cancer
Non‐surgical showed no clear difference in long‐term mortality (binary): definitive chemoradiotherapy versus… compared with surgical treatment of oesophageal cancer (primary outcomes) (low certainty).
1 finding from 1 review
Death from any cause (secondary outcome 3) · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC showed no clear difference in secondary outcome: all‐cause mortality at the end of compared with medical therapy (low certainty).
1 finding from 1 review
All‐cause mortality · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater
It is very uncertain whether evening changes all‐cause mortality compared with morning dosing regimen (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with unresectable hepatocellular carcinoma
Double‐dose adenovirus‐thymidine kinase with ganciclovir… may leads to lower all‐cause mortality compared with liver transplantation (low certainty).
1 finding from 1 review
All‐cause mortality · participants with unresectable hepatocellular carcinoma
It is very uncertain whether adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver… changes all‐cause mortality compared with liver transplantation (very low certainty).
1 finding from 1 review
All‐cause mortality
1 finding from 1 review
All‐cause mortality
1 finding from 1 review
All‐cause mortality
It is very uncertain whether summary of findings: Comparison 1 ‐ deferiprone (DFP) changes all‐cause mortality compared with deferoxamine (DFO) (very low certainty).
1 finding from 1 review
All‐cause mortality
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality
1 finding from 1 review
All‐cause mortality · pregnant women with fetal growth restriction
1 finding from 1 review
All‐cause mortality · adults with an open abdomen after surgery who have not experienced trauma
It is very uncertain whether NPWT changes all‐cause mortality compared with the Bogota bag (very low certainty).
1 finding from 1 review
All‐cause mortality · adults with an open abdomen after surgery who have not experienced trauma
It is very uncertain whether suprasorb CNP system changes all‐cause mortality compared with the ABThera system (very low certainty).
1 finding from 1 review
All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes all‐cause mortality compared with vitamin K antagonist (VKA) (very low certainty).
2 findings from 1 review
All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes all‐cause mortality compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether vitamin K antagonist (VKA) changes all‐cause mortality compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review